
MANE
Healthcare · Biotechnology · $5.47B market cap
$129.66-5.63 (-4.2%)Nov 13, 4:00 PM EST
Latest report
After the close
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Dec 31, 2026
EPS trend, 90 days to now · 0.0% over 90 days · 30-day revisions 0 up, 1 down
Beat estimates in 2 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Nov 10, 2026 | After the close | -0.59 | -0.50 | +15.3% |
| Aug 11, 2026 | After the close | -0.58 | -0.58 | 0.0% |
| May 15, 2026 | After the close | -0.85 | -0.73 | +14.2% |
| Mar 30, 2026 | After the close | -18.24 | -104.54 | -473.1% |
Veradermics, Incorporated, a clinical-stage biopharmaceutical company, focused on developing novel therapeutics for dermatologic and aesthetic conditions. The company develops treatments for Pattern Hair Loss affecting adults and children. The company's products include VDPHL01, an oral, non-hormonal treatment for men and women with PHL for chronic hair loss therapy. Additionally, it engages in the development of…